Corrigendum to 'Design and development of a series of borocycles as selective, covalent kallikrein 5 inhibitors' [Bioorg. Med. Chem. Lett. 29 (2019) 126675]

Bioorg Med Chem Lett. 2020 Jan 15;30(2):126771. doi: 10.1016/j.bmcl.2019.126771. Epub 2019 Dec 16.

Authors

Ann L Walker¹, Alexis Denis¹, Ryan P Bingham¹, Anne Bouillot¹, Emma V Edgar¹, Alan Ferrie¹, Duncan S Holmes¹, Alain Laroze¹, John Liddle², Marie-Helene Fouchet¹, Alexandre Moquette¹, Pam Nassau¹, Andrew C Pearce¹, Oxana Polyakova¹, Kathrine J Smith¹, Pamela Thomas¹, James H Thorpe¹, Lionel Trottet¹, Yichen Wang³, Alain Hovnanian³

Affiliations

¹ GlaxoSmithKline R&D, Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, UK.
² GlaxoSmithKline R&D, Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, UK. Electronic address: john.liddle@astrazeneca.com.
³ INSERM UMR1163 Laboratory of Genetic Skin Diseases, Imagine Institute and Université Paris Descarte-Sorbonne Paris Cité, Paris, France.

PMID: 31859161
DOI: 10.1016/j.bmcl.2019.126771

No abstract available

Publication types

Published Erratum